New York: Johnson & Johnson said Thursday that Joaquin Duato will transition to the role of CEO on January 3, replacing Alex Gorsky.
Gorsky, the CEO since 2012, is stepping aside “due to family health reasons,” according to a company press release, which said he will stay on as executive chairman.
Gorsky oversaw development of the company’s one-shot Covid-19 vaccine. His tenure also coincided with a 60 percent increase in research and development, the company said.
Duato is a three-decade veteran of J&J, as is Gorsky. He has served in his current role since 2018, guiding the drug and consumer product divisions, and overseeing supply-chain and technology operations.